KF
ANTH

Krilogy Financial’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Krilogy Financial’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-63
Closed – – 807
2017
Q1 		$0 Hold
63
– – ﹤0.01% 733
2016
Q4 		$0 Hold
63
– – ﹤0.01% 785
2016
Q3 		$2K Hold
63
– – ﹤0.01% 682
2016
Q2 		$2K Hold
63
– – ﹤0.01% 698
2016
Q1 		$2K Hold
63
– – ﹤0.01% 623
2015
Q4 		$2K Buy
+63
New +$2.78K ﹤0.01% 393

Other funds holding ANTH

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Krilogy Financial's ANTH Position: Q2 2017 in Review

Krilogy Financial sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2017, closing a stake of 63 shares.

Krilogy Financial first reported a position in ANTH in Q4 2015 and held it in 6 quarters. The position peaked at $2K in Q3 2016. 40 funds tracked by Wall St. Rank hold ANTH as of Q2 2017.

  • Krilogy Financial reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Krilogy Financial sold 63 Anthera Pharmaceuticals, Inc. shares in Q2 2017.
  • Krilogy Financial first reported a position in Anthera Pharmaceuticals, Inc. in Q4 2015 and held it in 6 quarters.
  • Krilogy Financial's Anthera Pharmaceuticals, Inc. position peaked at $2K in Q3 2016.
  • 40 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2017.

Based on Krilogy Financial's 13F filing for Q2 2017, filed 15 Aug 2017.